Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access

May 9, 2020 1:31 AM UTC

Cash from an ex-U.S. licensing deal with Santen, plus years of grants from CIRM, position jCyte to bring its genetic blindness stem cell therapy into pivotal studies.

Santen Pharmaceutical Co. Ltd. (Tokyo:4536) will receive exclusive rights to jCell in regions that include Europe and Asia. The human allogeneic retinal progenitor cell therapy is in the crossover portion of a Phase IIb study to treat retinitis pigmentosa...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article